Nivolumab

GPTKB entity

Properties (57)
Predicate Object
gptkbp:instanceOf monoclonal antibody
gptkbp:administrativeDivision every 2 weeks
every 4 weeks after initial treatment
gptkbp:approves gptkb:FDA
gptkbp:clinicalTrials ongoing
Phase II
Phase III
Phase I
first-line therapy
second-line therapy
gptkbp:contraindication hepatitis
autoimmune diseases
pneumonitis
colitis
endocrinopathies
history of severe hypersensitivity
gptkbp:developedBy gptkb:Bristol-Myers_Squibb
gptkbp:dosageForm 3 mg/kg every 2 weeks
gptkbp:drugInterdiction long half-life
increases T-cell activity
gptkbp:formulation solution for infusion
gptkbp:hasCapacity educational resources
financial assistance programs
nurse helpline
gptkbp:hasPopulation adults
pediatric patients in trials
https://www.w3.org/2000/01/rdf-schema#label Nivolumab
gptkbp:interactsWith corticosteroids
other immunotherapies
gptkbp:is_monitored_by liver function tests
thyroid function tests
gptkbp:issuedBy intravenous infusion
gptkbp:lastProduced 2014
gptkbp:mandates gptkb:melanoma
renal cell carcinoma
non-small cell lung cancer
gptkbp:marketedAs gptkb:Opdivo
gptkbp:patentStatus patented
expiring in 2026
gptkbp:researchAreas combination therapies
biomarkers for response
gptkbp:researchInterest improved overall survival
durable responses
less toxicity than chemotherapy
gptkbp:resources ASCO guidelines
NCCN_guidelines
gptkbp:route intravenous
gptkbp:sideEffect fatigue
diarrhea
rash
immune-related adverse events
gptkbp:storage refrigerated
protected from light
gptkbp:targets PD-1
gptkbp:triggerType immune checkpoint inhibitor
gptkbp:usedFor treatment of cancer
gptkbp:variant ipilimumab